# Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT02319135** · PHASE3 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 289 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitadine
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Lenograstim
- **DRUG:** Filgastrim

## Key facts

- **NCT ID:** NCT02319135
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-10-28
- **Final completion:** 2019-10-28
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2020-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319135, "Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02319135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*